- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.04. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 17.04. | Tevogen Bio Inc: Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility | 92 | GlobeNewswire (Europe) | The agreement would facilitate providing Tevogen Bio with in-house cell therapy production capabilitiesFormalized agreement aligns with previously announced topline forecasts WARREN, N.J., April... ► Artikel lesen | |
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 15.04. | Tevogen Bio Inc: Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction | 555 | GlobeNewswire (Europe) | WARREN, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced the commission of Databricks, Inc., a leader in data, analytics... ► Artikel lesen | |
| 09.04. | Tevogen Bio Inc: Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States | 88 | GlobeNewswire (Europe) | WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announces its newest effort: Tevogen Generics. This effort is in response... ► Artikel lesen | |
| 09.04. | Tevogen Bio Inc: Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs | 1 | GlobeNewswire (USA) | ||
| 07.04. | Tevogen reports high insider ownership amid market volatility | 1 | Investing.com | ||
| 07.04. | Tevogen Bio Inc: Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission | 103 | GlobeNewswire (Europe) | WARREN, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), a healthcare company with dedicated efforts in immunotherapy and artificial intelligence... ► Artikel lesen | |
| 05.04. | Tevogen Bio zeigt Fortschritte bei Quartalszahlen | 2 | IT BOLTWISE | ||
| 02.04. | Tevogen Bio Holdings Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 01.04. | Tevogen Bio Holdings Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 26.03. | Tevogen Bio Inc: Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast | 1 | GlobeNewswire (USA) | ||
| 25.03. | Tevogen Bio appoints new head of government affairs | 3 | Investing.com | ||
| 25.03. | Tevogen Bio ernennt neuen Leiter für Regierungsangelegenheiten | 3 | Investing.com Deutsch | ||
| 25.03. | Tevogen Bio Inc: Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan | 121 | GlobeNewswire (Europe) | WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven... ► Artikel lesen | |
| 10.03. | Tevogen Bio reicht Patent für T-Zell-fokussierten Impfstoff ein | 2 | Investing.com Deutsch | ||
| 10.03. | Tevogen Bio Inc: Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO | 202 | GlobeNewswire (Europe) | Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company's lead product candidate TVGN 489, to mitigate the risk posed by... ► Artikel lesen | |
| 08.03. | Tevogen Bio Holdings Inc. (TVGN) Secures $8M Grant, Accelerates AI Initiatives with Microsoft | 3 | Insider Monkey | ||
| 07.03. | Tevogen Bio Inc: Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel | 2 | GlobeNewswire (USA) | ||
| 04.03. | Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential | - | Benzinga.com | ||
| 04.03. | This Tevogen Bio Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | 5 | Benzinga.com |
Seite:
1 2 3 4 5 Weiter >>
87 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,610 | +0,17 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| AMGEN | 245,50 | -0,10 % | Amgen im Stresstest - fällt die Biotech-Aktie zurück in die alte Seitwärtsrange? | Anzeige / WerbungDie Aktie von Amgen (ISIN: US0311621009) hatte sich zu Jahresbeginn beeindruckend aus dem Konsolidierungsmuster gelöst. Doch die jüngste Korrektur hat Spuren hinterlassen - und stellt... ► Artikel lesen | |
| NOVAVAX | 6,191 | -0,10 % | Novavax Aktie: Optimistische Umsatzprognosen! | Die Novavax-Aktie gewinnt über 20% nach positiven Signalen der FDA zur COVID-19-Impfstoffzulassung. Weitere Studien sind jedoch erforderlich. Die Novavax-Aktie zeigt heute eine beeindruckende Rallye... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,188 | +2,96 % | Palatin's Phase 2 Obesity Study Shows Encouraging Appetite Suppression Data, Stock Up In Pre-Market | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTN), Thursday announced results from its BMT-801 Phase 2 obesity study, which evaluated the co-administration of melanocortin 4 receptor or... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 524,20 | -0,38 % | Regeneron Pharma Partners With FujiFilm Diosynth To Boost Capacity At $3 Bln Investment |
WASHINGTON (dpa-AFX) - Regeneron Pharma, Inc. (REGN), a biotechnology company, on Tuesday announced a major expansion of its manufacturing capacity through a new agreement with FujiFilm Diosynth... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,680 | -0,59 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem unterzeichnet strategische Beteiligungsvereinbarung und gründet neues Joint Venture mit Promura GmbH | Vancouver, British Columbia - 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC:
SRBCF) ("Sirona"), ein Biotechnologieunternehmen, das auf kosmetische Inhaltsstoffe... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,540 | +0,79 % | COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer | 25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,084 | -1,83 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2025 Financial Results on May 5 | ||
| BIOMARIN PHARMACEUTICAL | 53,90 | -2,14 % | Oppenheimer maintains BioMarin stock Outperform with $98 target | ||
| NUREXONE BIOLOGIC | 0,447 | +8,50 % | NurExone Biologic Inc.: NurExone ernennt Biotech-Branchenführer - Jacob Licht soll die US-Operationen und die Exo-Top-Produktionserweiterung leiten und vollendet die Verlegung nach Ontario | TORONTO und HAIFA, Israel, 22. April 2025 -- NurExone
Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" oder das "Unternehmen"), ein biotechnologisches Unternehmen in der präklinischen... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 11,365 | -2,99 % | Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results | PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting... ► Artikel lesen | |
| XOMA ROYALTY | 20,800 | -1,89 % | Spotlight Stock Market: Market Notice 68/25 - Information regarding the rights issue from Xoma AB | ||
| T2 BIOSYSTEMS | 0,077 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,220 | 0,00 % | Phio Pharmaceuticals Corp. - 8-K, Current Report |
Das Unternehmen TEVOGEN BIO HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,038 (+4,61 %) liegt der Kurs bei 0,862 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.
